Molecular Endocrinology Laboratory, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montréal, QC, Canada H2W 1R7.
Diabetologia. 2011 Sep;54(9):2368-80. doi: 10.1007/s00125-011-2212-7. Epub 2011 Jun 19.
AIMS/HYPOTHESIS: We sought to characterise novel genes dysregulated by sex hormonal imbalances that induce obesity and metabolic disorder in a setting of oestrogen deficiency and androgen dominance in follicle-stimulating hormone receptor (For [also known as Fshr]) knockout female mice.
Transcriptome analysis of mesenteric adipose tissue (MAT) of mutants revealed novel genes. One novel gene named Meda-7 was selected for study. Meda-7 was cloned from mouse and human adipose tissue; its expression, hormonal regulation and function were characterised.
Mouse Meda-7 is richly expressed in deep visceral adipose tissue and encodes a 22 kDa secreted protein with 71% homology to human mesenteric oestrogen-dependent adipose gene- 7 (MEDA-7) protein. Both have six conserved cysteines like many cytokines. In obese patients, MEDA-7 is more abundant in omental than subcutaneous fat. Meda-7 is downregulated in For-knockout female MAT at 5 months (obese state) followed by steep upregulation at 9 months (prediabetic condition) when mutants progress towards the metabolic syndrome. Meda-7 is expressed predominantly in the stromal-vascular cell fraction. In this fraction,M1-proinflammatorymacrophages are rich in Meda-7. Meda-7 dysregulation in 5-month-old For-knockout MAT is restored by oestrogen, but treatment has no effect in older mutants. Overabundance of MEDA-7 in HEK-293 cells enhances cell proliferation via p42/44 mitogen-activated protein kinases. Secreted MEDA-7 attenuates insulin-stimulated glucose uptake in 3T3-L1 adipocytes, while downregulating glucose transporter-4 and upregulating both monocyte chemotactic protein-1 and suppressor of cytokine signalling-3. Downstream activity of the insulin signalling mediator, phospho-AKT, is also downregulated.
CONCLUSIONS/INTERPRETATION: MEDA-7 is a hormone-regulated adipokine/proinflammatory cytokine that is implicated in causing chronic inflammation, affecting cellular expansion and blunting insulin response in adipocytes.
目的/假设:我们试图描述在卵泡刺激素受体(也称为 Fshr)敲除雌性小鼠雌激素缺乏和雄激素优势的情况下,由性激素失衡失调引起的肥胖和代谢紊乱的新型基因。
对突变体肠系膜脂肪组织(MAT)的转录组分析揭示了新的基因。选择了一种名为 Meda-7 的新基因进行研究。从鼠和人脂肪组织中克隆出 Meda-7;研究了其表达、激素调节和功能。
鼠 Meda-7 在深内脏脂肪组织中表达丰富,编码一种 22 kDa 的分泌蛋白,与人肠系膜雌激素依赖性脂肪基因-7(MEDA-7)蛋白具有 71%的同源性。两者都像许多细胞因子一样具有六个保守的半胱氨酸。在肥胖患者中,MEDA-7 在网膜脂肪中比皮下脂肪中更为丰富。在 5 个月(肥胖状态)时,For 敲除雌性 MAT 中的 Meda-7 下调,随后在 9 个月(糖尿病前期状态)时急剧上调,此时突变体向代谢综合征发展。Meda-7 主要在基质-血管细胞部分表达。在这个部分,M1 促炎巨噬细胞富含 Meda-7。5 个月大的 For 敲除 MAT 中的 Meda-7 失调可被雌激素恢复,但在老年突变体中治疗无效。过多的 MEDA-7 在 HEK-293 细胞中通过 p42/44 丝裂原活化蛋白激酶增强细胞增殖。分泌的 MEDA-7 减弱 3T3-L1 脂肪细胞中胰岛素刺激的葡萄糖摄取,同时下调葡萄糖转运蛋白-4,上调单核细胞趋化蛋白-1 和细胞因子信号转导抑制因子-3。胰岛素信号转导介质磷酸化-AKT 的下游活性也被下调。
结论/解释:MEDA-7 是一种受激素调节的脂肪因子/促炎细胞因子,它参与引起慢性炎症,影响细胞扩张,并削弱脂肪细胞对胰岛素的反应。